Treeline Biosciences is a clinical-stage biotechnology company developing precision medicines for cancer and other serious diseases. Founded in 2021 with significant financial backing, the company focuses on historically difficult-to-drug molecular targets in oncology and has recently advanced three distinct therapeutic candidates into Phase 1 clinical trials.
TLN-372 is an internally developed small molecule inhibitor designed to target multiple mutations in the KRAS gene. These mutations are common drivers in various solid tumors, including those affecting the lung, colon, and pancreas.
This therapeutic addresses the long-standing challenge of effectively drugging the KRAS protein, which is one of the most frequently mutated oncogenes in human cancers and has been notoriously difficult to inhibit.
The company addresses the critical need for effective treatments for patients with cancers that have either become resistant to existing therapies or have historically lacked targeted treatment options due to the complexity of their underlying genetic drivers.